Equities research analysts expect XBiotech Inc (NASDAQ:XBIT) to report earnings per share of ($0.15) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for XBiotech’s earnings. XBiotech reported earnings of ($0.16) per share during the same quarter last year, which indicates a positive year over year growth rate of 6.3%. The business is scheduled to issue its next earnings report on Thursday, August 8th.
On average, analysts expect that XBiotech will report full-year earnings of ($0.61) per share for the current financial year. For the next year, analysts anticipate that the business will report earnings of ($0.85) per share. Zacks’ EPS calculations are an average based on a survey of analysts that cover XBiotech.
XBiotech (NASDAQ:XBIT) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter.
NASDAQ:XBIT traded up $0.10 on Friday, reaching $7.39. The company’s stock had a trading volume of 5,715 shares, compared to its average volume of 242,893. XBiotech has a 12-month low of $2.13 and a 12-month high of $11.74. The firm has a market capitalization of $263.60 million, a price-to-earnings ratio of -12.63 and a beta of 0.47. The company has a 50 day moving average of $8.21.
In related news, major shareholder Fondation Rennes bought 1,200,000 shares of the stock in a transaction that occurred on Tuesday, June 4th. The stock was purchased at an average cost of $8.25 per share, with a total value of $9,900,000.00. Following the purchase, the insider now directly owns 5,110,282 shares of the company’s stock, valued at approximately $42,159,826.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 33.40% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of XBiotech by 5.5% during the 3rd quarter. Vanguard Group Inc. now owns 834,523 shares of the biopharmaceutical company’s stock valued at $2,654,000 after acquiring an additional 43,648 shares during the period. Tibra Equities Europe Ltd bought a new position in shares of XBiotech during the 1st quarter valued at approximately $750,000. Birchview Capital LP bought a new position in shares of XBiotech during the 1st quarter valued at approximately $110,000. Finally, Marshall Wace LLP bought a new position in shares of XBiotech during the 1st quarter valued at approximately $682,000. 7.05% of the stock is owned by institutional investors and hedge funds.
XBiotech Company Profile
XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.
Further Reading: Is it Safe to Invest in Commodities?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.